S. Pignata, S. C. Cecere, and M. Di Maio, “Bevacizumab as first-line treatment of ovarian cancer: strengths and weaknesses of subgroup analyses:  ”, CBN, vol. 4, no. 1, pp. 45–47, Mar. 2016.